C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in C4 Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 117
- +4 vs. Q3 2022
- Shares held
- 39.2M
- −213.8K (−0.5%) vs. Q3 2022
- Total value
- $231.4M
- −$114.4M (−33.1%) vs. Q3 2022
- New holders
- 17
- 42 more added
- Sold out
- 13
- 33 more reduced
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CCCC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 147 | $547.6M |
| Q1 2026 | 123 | $221.3M |
| Q4 2025 | 101 | $152.5M |
| Q3 2025 | 97 | $116.6M |
| Q2 2025 | 102 | $78.2M |
| Q1 2025 | 115 | $102.6M |
| Q4 2024 | 113 | $231.8M |
| Q3 2024 | 118 | $365.9M |
| Q2 2024 | 115 | $281.3M |
| Q1 2024 | 106 | $475.6M |
| Q4 2023 | 92 | $265.6M |
| Q3 2023 | 84 | $64.5M |
| Q2 2023 | 100 | $94.1M |
| Q1 2023 | 121 | $117.5M |
| Q4 2022 | 117 | $231.4M |
| Q3 2022 | 114 | $345.9M |
| Q2 2022 | 113 | $297.2M |
| Q1 2022 | 125 | $904.8M |
| Q4 2021 | 119 | $1.15B |
| Q3 2021 | 113 | $1.54B |
| Q2 2021 | 107 | $1.21B |
| Q1 2021 | 83 | $926.8M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding C4 Therapeutics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nuveen Asset Management, LLC | 377,524 | $2.23M | 0.00% | −24,360−6.1% | Reduced |
| Morgan Stanley | 379,199 | $2.24M | 0.00% | +34,812+10.1% | Added |
| Citadel Advisors LLC | 379,500 | $2.24M | 0.00% | +249,713+192.4% | Added |
| Dimensional Fund Advisors LP | 379,782 | $2.24M | 0.00% | +353,704+1,356.3% | Added |
| Northern Trust Corp | 399,032 | $2.35M | 0.00% | +17,049+4.5% | Added |
| Jacobs Levy Equity Management, Inc | 728,671 | $4.30M | 0.03% | −10,322−1.4% | Reduced |
| Janus Henderson Group PLC | 738,629 | $4.36M | 0.00% | −80,118−9.8% | Reduced |
| Geode Capital Management, LLC | 797,292 | $4.70M | 0.00% | +20,070+2.6% | Added |
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $9.69M | 1.08% | 00.0% | Unchanged |
| Vanguard Group Inc | 2,064,915 | $12.2M | 0.00% | +45,261+2.2% | Added |
| Soleus Capital Management, L.P. | 2,440,843 | $14.4M | 2.07% | +999,330+69.3% | Added |
| State Street Corp | 2,447,597 | $14.4M | 0.00% | +485,785+24.8% | Added |
| RTW Investments, LP | 2,819,472 | $16.6M | 0.34% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 2,925,253 | $17.3M | 0.00% | −38,803−1.3% | Reduced |
| BlackRock Inc. | 3,621,133 | $21.4M | 0.00% | +156,561+4.5% | Added |
| Wasatch Advisors Inc | 5,775,698 | $34.1M | 0.23% | −158,778−2.7% | Reduced |
| ArrowMark Colorado Holdings LLC | 5,802,871 | $34.2M | 0.41% | +710,896+14.0% | Added |
| Pictet Asset Management SA | 0 | $0 | 0.00% | −1,305,349−100.0% | Sold out |
| Perceptive Advisors LLC | 0 | $0 | 0.00% | −766,231−100.0% | Sold out |
| T. Rowe Price Investment Management, Inc. | 0 | $0 | 0.00% | −547,667−100.0% | Sold out |
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −107,568−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −57,088−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −31,512−100.0% | Sold out |
| Alps Advisors Inc | 0 | $0 | 0.00% | −26,696−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −24,134−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −23,861−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −14,822−100.0% | Sold out |
| B. Metzler seel. Sohn & Co. AG | 0 | $0 | 0.00% | −14,700−100.0% | Sold out |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −7,230−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −6,209−100.0% | Sold out |
| Regentatlantic Capital LLC | – | – | – | – | Not filed |